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ABSTRACT
Introduction: Duration of untreated psychosis (time
between the onset of symptoms and start of treatment)
is considered the strongest predictor of symptom
severity and outcome. Integrated care pathways that
prescribe timeframes around access and interventions
can potentially improve quality of care.
Methods and analysis: A multicentre mixed
methods study to assess feasibility, acceptability,
effectiveness and analysis of direct costs of an
integrated care pathway for psychosis. A pragmatic,
non-randomised, controlled trial design is used to
compare the impact of Treatment and Recovery In
PsycHosis (TRIumPH; Intervention) by comparison
between NHS organisations that adopt TRIumPH and
those that continue with care as usual (Control).
Quantitative and qualitative methods will be used. We
will use routinely collected quantitative data and study-
specific questionnaires and focus groups to compare
service user outcomes, satisfaction and adherence to
intervention between sites that adopt TRIumPH versus
sites that continue with usual care pathways.
Setting: 4 UK Mental health organisations. Two will
implement TRIumPH whereas two will continue care as
usual.
Participants: Staff, carers, individuals accepted to
early intervention in psychosis teams in participating
organisations for the study period.
Intervention: TRIumPH—Integrated Care Pathway for
psychosis that has a holistic approach and prescribes
time frames against interventions; developed using
intelligence from data; co-produced with patients,
carers, clinicians and other stakeholders.
Outcomes: Feasibility will be assessed through
adherence to the process measures. Satisfaction and
acceptability will be assessed using questionnaires and
focus groups. Effectiveness will be assessed through
data collection and evaluation of patient outcomes,
including clinical, functional and recovery outcomes,
physical health, acute care use. Outcome measures will
be assessed at baseline, 12 and 24 months to measure
whether there is an effect and if so, whether this is
sustained over time. Outcomes measures at the
adopter sites will be compared to their own baseline
and against comparator sites.
Ethics and dissemination: Ethics approval was
obtained from East of Scotland Research Ethics Service
(REC Ref no: LR/15/ES/0091). The results will be
disseminated through publications, conference
presentations, reports to the organisation.
Study registration: UK Clinical Research Network
Portfolio: 19187.
BACKGROUND
Pooled incidence of all psychoses in the UK
is documented at 31.7/100 000 person-years.1
Evidence suggests that ﬁrst episode psychosis
occurs more often in young men; a second-
ary peak in the ﬁrst episode is seen in
Strengths and limitations of this study
▪ Robust methodology used for development of
the pathway;
▪ One of the few service evaluation studies;
▪ Evaluation of direct costs is an integral part of
the study;
▪ Results will be generalisable to NHS organisa-
tions, but there may be challenges in inter-
national adoption;
▪ Limited resources within services to deliver care
along the pathway may impact on results.
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women around the age of 45 years. The occurrence of
new episodes is higher in some black and minority
ethnic groups. Psychosis is more common in urban
populations, particularly in deprived areas. The course is
usually recurrent, with signiﬁcant health service use
(and associated costs), especially at ‘crisis’ points with
inpatient bed usage.1 2 Life expectancy is reduced by
∼15–20 years, mostly as a consequence of physical health
problems.3
Schizophrenia, the most burdensome of psychoses, is
among the most costly illnesses worldwide. According to
the Global Burden of Disease Study, schizophrenia
causes a high degree of disability, which accounts for
1.1% of the total disability-adjusted life years (DALYs)
and 2.8% of years lived with disability (YLDs). In the
WHO report, schizophrenia is listed as the 8th leading
cause of DALYs worldwide in the age group 15–
44 years.4 In addition to the direct cost, there is a consid-
erable burden on the relatives.5
The longer the time between the onset of symptoms
of psychosis and the start of treatment—known as the
duration of untreated psychosis (DUP)—the worse the
outlook, more so for social functioning and recovery.6 7
Therefore, DUP is considered to be the strongest pre-
dictor of symptom severity and prognosis.8 Evidence
from trans-cultural and international research suggests
that DUP ranges between 364 and 721 days9 10 and redu-
cing DUP is of imminent national and international
importance.4 Therefore, the pathway goals are to iden-
tify the illness as early as possible, treat the symptoms,
provide skills to patients and their families, maintain the
improvement over a period, prevent relapses and reinte-
grate the individuals into the community so that they
can lead as normal a life as possible.5
Longer durations of untreated psychosis can occur
due to client-related or service-related factors, or both.
Client-related factors could be attributable to an inability
to recognise early symptoms or due to the illness itself
such as poor insight, social and emotional withdrawal11
or due to cultural values systems like attributions to
illness and help-seeking pathways into care.12 13
There is a considerable unmet need currently in
patients with psychosis in the way they can access services
and receive evidence-based treatments as prescribed by
the National Institute for Health and Care Excellence
(NICE)14 in a timely fashion. The Schizophrenia
Commission Report15 and National Audit of
Schizophrenia16 have highlighted deﬁciencies in psycho-
pharmacological and psychological care and recom-
mended changes to the way care is provided to patients
with schizophrenia. There is strong cost-effectiveness
argument supporting early intervention and early inter-
vention in psychosis (EIP) teams were developed in
many countries to achieve this goal, but, in attempts to
reduce costs, these teams have been diluted in many
areas.17 Community education and awareness campaigns
have been tried to identify symptoms early with limited
success.18 Educating general practitioners to reduce
delays in referrals to secondary care services has had
limited impact19 in increasing the number of referrals.
Delays in secondary care mental health services have
been found to be of most signiﬁcance in the care path-
ways of those with long DUP.20 21
Therefore, there is a need for integrated pathways pre-
scribing key stages, timelines and interventions matched
to the diversity of presentations that occur with psych-
osis, for example, comorbidity with substance misuse
and trauma, which will improve access to evidence-based
services, interventions and support recovery.
Integrated pathways are also fundamental to impro-
ving the physical health and reducing premature mor-
bidity and mortality in people with psychosis. Pathways
can ensure delivery of appropriate health promotion at
key stages, for example, weight gain from antipsychotic
medication is especially pronounced in the ﬁrst 8 weeks
of administration but it is rare that speciﬁc support is
offered at this stage. Similarly smoking cessation support
can be built in at critical periods, for example, on admis-
sion to hospital. Integrated pathways improve the quality
of care by improving multidisciplinary communication,
care planning, including primary care, and patient
satisfaction.22
RESEARCH QUESTION
Is implementation of TRIumPH integrated pathway in
services feasible and acceptable and does it reduce dur-
ation of untreated psychosis, hospital stay and severity of
symptoms at 12 and 24 months?
Study objectives
The primary objective of this study was to assess the
feasibility, acceptability and effectiveness of the psychosis
pathway, TRIumPH. The secondary objective is to
conduct an evaluation of direct costs and to explore bar-
riers to implementation of the pathway with staff.
METHODS
Study design
This is a multicentre, non-randomised, mixed-method
study to evaluate feasibility, acceptability, effectiveness
and analysis of direct costs (eg, care cost, hospital bed
costs etc) of an integrated care pathway, TRIumPH.
Qualitative and quantitative data will be collected and
analysed.
Setting
The study has two adopter organisations—early interven-
tion in psychosis teams in Southern Health NHS
Foundation Trust and Shefﬁeld Health and Social Care
NHS Foundation Trust and two comparator organisa-
tions—EIP teams in Solent NHS Trust and Dorset
Healthcare University NHS Foundation Trust.
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The intervention: TRIumPH—integrated care pathway
TRIumPH is an integrated care pathway for psychosis
that prescribes time frames around access and clinical
interventions as developed in the UK (ﬁgures 1 and 2) .23
The work has used a similar approach to that taken to
improve care in other health areas like stroke care,
where there has been a demonstrable improvement in
outcomes for patients and carers. This new psychosis
pathway aims to reduce the impact of disease and
promote recovery by ensuring that every individual gets
the best evidence-based care at the right time and in the
right place.
In developing the pathway, a multipronged approach
has been used, using (i) intelligence from information,
(ii) co-production with individuals with lived experience
of mental illness and their carers and (iii) engagement
with clinicians and other stakeholders, including com-
missioners, primary care and third-sector organisations.
The approach has used a robust methodology that can
be adapted and adopted nationally and internationally.
Intelligence from information
In developing the psychosis pathway, the Wessex
Academic Health Sciences Network (AHSN) commis-
sioned Janssen Healthcare Innovation to build a com-
prehensive picture of service use in Wessex from
national data sets by pseudonymising, non-sensitive
patient-level data for 2012–2013. Licensed from the
Health and Social Care Information Centre, the Mental
Health Minimum Data Set (MHMDS), and Hospital
Episode Statistics (HES) were searched for individuals
identiﬁed using the relevant ICD-10 clinical codes;
Mental health (Payment by Results) PbR clusters and
Health of the Nation Outcome Scale (HoNOS). The
data conﬁrmed that individuals who suffered with
psychosis:23
▸ Had higher psychiatric hospital admissions with
longer stays (on average over 50% longer than other
mental health conditions);
▸ Accounted for the majority of community health pro-
fessional contacts (around three times more);
▸ Had more attendances and admissions to local acci-
dent and emergency departments
▸ Are keen to work but could not ﬁnd employment.
Limitations with the data and method used were
acknowledged. The information on service use was con-
sistent with other areas in the country.23
Coproduction
The Wessex AHSN supported co-production workshops
that enabled patient, carer and clinician feedback. The
aim of the coproduction workshops was to understand
Figure 1 TRIumPH pathway—routine referral.
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opportunities and challenges of current service provi-
sion and understand how ‘experts by lived experience’
would like to see services improve. Southampton volun-
tary services (UK) provided rooms for the workshops
that were attended by integrated stakeholders—20
patients from across Hampshire, 3 carers and 5 health-
care professionals—and lasted 4 hours. The workshops
were facilitated by Stripes partners (a global strategy and
innovation studio that support organisations to under-
stand their customers better by providing a fresh per-
spective and a deep understanding ie, then shared by
the team collectively) to establish a ‘bottom-up’ under-
standing of priorities speciﬁc to Wessex.
Following an ice breaker exercise, participants were
asked to write about their ‘hopes and fears.’ In the
second stage, rather than start with any assumptions, the
facilitators let participants deﬁne what was important to
them by asking them to write postcards about a chosen
experience and address it to a person who they felt
should hear their story. Hundreds of postcards were
obtained, yielding many ﬁrst-hand experiences of
current care. The feedback was then collated into
themes by the facilitators. The themes were then rated
by individual participants in terms of importance and
experiences in different settings.23 Below are the key
themes rated as high priority with examples of quotes
from the participants:
▸ Prevention: ‘I was introduced to the system after I com-
mitted a crime. It could have been avoided if I had
received the right support and intervention’.
▸ Consistent: ‘My brother always complains that his
carers and Psychiatrists change all the time, he tells
one person all about himself and then, some months
or weeks later, he has to tell it all over again. He says
he gets fed up with this’.
▸ Responsive: ‘If services intervened early, hospitalisation
could have been avoided. If I had been able to get
rapid response might also have avoided crisis’.
▸ Empathetic: ‘My husband called the hospital at home
team and he did not feel listened to’.
▸ Seamless: ‘The most difﬁcult aspect of my care is that
since I moved there is little communication between
agencies’.
This approach helped us to understand what was
intrinsically important to patients and carers, rather
than relying on assumptions.
The pathway attempts to address the key areas, as stan-
dardising care improves quality through multidisciplin-
ary communication using care planning that makes care
consistent, seamless and responsive. The pathway
emphasises prevention through communication with
primary care and reduction in DUP; it emphasises con-
sistency and seamless care through a prescribed standar-
dised approach in every phase; responsiveness through
Figure 2 TRIumPH pathway—crisis pathway.
4 Rathod S, et al. BMJ Open 2016;6:e012751. doi:10.1136/bmjopen-2016-012751
Open Access
 o
n
 15 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-012751 on 21 December 2016. Downloaded from 
early access and interventions. Through a standardised
approach to assessment and treatment, it promotes
empathy.
Engagement with clinicians and stakeholders
Wider engagement events were held with patients,
carers, clinicians, managers and wider stakeholders like
commissioners, academics and these also gained polit-
ical support. Feedback can be viewed on: http://
wessexahsn.org.uk/programmes/show/5/mental-health
A steering group was then set up, involving clinicians,
commissioners, patient and carer representatives,
general practitioners and other stakeholders who were
essential to the development of the pathway.
Information from the acquired data and coproduction
workshops were triangulated with clinical expertise and
national evidence to chart process maps.24 The process
map identiﬁed the scope of the pathway and key out-
comes desired, including the speciﬁc timeframes for
access and intervention and highlight the potential chal-
lenges and opportunities.23
The pathway has been implemented in the EIP teams
of two organisations, called the adopter sites. In imple-
menting the pathway, a multipronged approach has
been used, including training of EIP team clinicians and
development of a guide supporting the pathway; estab-
lishment of a pathway facilitator and collection and dis-
cussion of live data in clinical teams.
EIP team training and guide
A guide on how to use the pathway has been produced
and placed on the trust website. All participant EIP
teams in adopter sites have received information and
training on different aspects of implementing the
pathway. Training has followed the philosophy and psy-
chological principles that underpin quality improvement
initiatives. Training has also been provided on key
aspects of care like how to conduct physical health
examination; how to deal with comorbidity of alcohol
and substance misuse among other aspects.
Pathway facilitator
A pathway facilitator role has been established within
the EIP teams. The facilitator supports the EIP teams in
adopter sites to implement the pathway and maintain
consistency and ﬁdelity to the model.
Continuous improvement through use of data
Regular data collection and feedback to clinicians, man-
agers and the pathway steering group has been inform-
ing effective implementation of the pathway.
This pathway needs to be evaluated for its feasibility,
acceptability, effectiveness and direct costs. Therefore,
this study will:
1. Assess the feasibility of implementing the pathway
from the perspective of patients, carers and staff
2. Measure patient outcomes to assess effectiveness of
the pathway
3. Assess the acceptability of the pathway to patients,
carers and clinicians.
4. Evaluate direct costs (eg, care cost, hospital bed costs
etc) of the pathway
Control—care as usual
Participants in the control arm will receive care as usual.
There is a signiﬁcant variability in provision of care,
despite NICE guidelines on treatment and management
of ﬁrst episode psychosis.14 The study team will record
any uptake of NICE recommended programmes during
the study, and collate information from centres about
uptake of NICE recommendations more widely. These
organisations are similar to the adopter sites in that they
aspire to follow the EIP policy implementation guide
and meet the access and waiting time (AWT) standard.
There are also differences as there is a variability in the
way care is provided in each team and organisation
depending on culture of the team, resources allocated
and leadership.
Outcome measures
Feasibility and acceptability of the pathway will be
assessed through quantitative and qualitative data collec-
tion regarding adherence to the process measures of
the pathway, including timeliness of access and interven-
tion; type of intervention offered, including medication,
physical health assessment, psychological intervention
etc and reasons for deviation from the pathway.
Additionally, satisfaction and acceptability will be
assessed using questionnaires and focus groups consist-
ing of the following qualitative methods; patient experi-
ence using speciﬁcally designed patient experience
questionnaires and focus groups, staff experience using
staff questionnaires designed to measure the impact of
the pathway on staff experience and carer experience
using carer focus groups.
Effectiveness will be assessed through data collection
and evaluation in patient outcomes, including clinical
(eg, HoNOS: Health of Nation Outcome Score), func-
tional and recovery outcomes (eg, employment, voca-
tion, physical health), among other measures. Analysis
of direct costs will be measured through a change in
service use (eg, routinely collected data on crisis, admis-
sions, detentions, Emergency Department (ED) atten-
dances). See table 1 for full details.
All outcome measures will be assessed at baseline and
after 12 and 24 months to measure if there is an effect
and if so, whether this is sustained over the longer term.
Outcomes measures at the adopter sites will be com-
pared to their own baseline and against comparator
sites.
Sample size
As this is a feasibility prospective study, no a priori power
and sample size calculations have been performed.
Instead, data for all available patients and staff during
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the study period as a convenience sample of consecutive
participants will be used.
Selection criteria
1. Routinely collected data on every patient that are
accepted by the EIP teams in participant organisa-
tions during the study period.
2. Patient questionnaires and focus groups:
Participants will be eligible for inclusion in the study if
they are:
▸ On the EIP caseloads,
▸ Are able to give written informed consent,
▸ Are able and willing to attend and participate in a
focus group,
▸ Are able to speak and read English.
Participants are excluded from the study if they have a:
▸ Acute episode of mental illness that could seriously
reduce their ability to consent and understand the
information,
▸ Signiﬁcant alcohol or substance misuse which, in the
opinion of the principal investigator, would limit the
patient’s ability to participate in the study due to lack
of ability to understand the information,
▸ Diagnosis of learning disability that impacts on cap-
acity to consent and understand the information,
3. Staff questionnaires: anonymous questionnaires will
be offered to all staff in Adult mental health services
in all the participant sites at baseline and at follow-up.
4. Carer focus groups: carers of patients on EIP case-
loads who are willing and have the capacity to consent
will be invited.
Recruitment of participants for questionnaires
The study will be promoted within clinical teams and in
areas where mental health services are delivered.
Research facilitators will work with EIP clinical teams
within the participant mental health trusts to identify
potentially eligible participants from their caseload for
questionnaire surveys and focus groups.
Every patient with psychosis that is accepted by the
EIP teams during the study period in the participant
teams identiﬁed through their care workers and those
who meet the inclusion criteria will receive the question-
naire. During the study, no personal information will be
collected other than a person’s name for consent pur-
poses and telephone number for contact purposes.
Every staff member from adult mental health in the
Table 1 TRIumPH study quantitative outcome measures
Demographic data (age, gender, ethnicity, employment, housing) Acute care
Process outcomes Contact acute MH services (in EIP)
Referral source Date acute mental health admission
Central triage point Acute mental health service/Inpatient Screening
within 4hrs
Time from referral to assessment MHA (Mental Health Act) information
DNA’s (did not attend) prior to assessment Date of discharge from acute care
Time to allocation and engagement by care coordinator Date crisis plan completed
Time to multidisciplinary team (MDT) discussion Number of subsequent acute admissions
Time to medical formulation Date of attendance at ED
Time to CPA (care plan approach)/care plan Reason for ED attendance
Time from referral to intervention offered Date of general hospital admission (in EIP)
Type of intervention (NICE approved) Date general hospital discharge
Time to carer support assessment offered Contact with criminal justice system
Time to ISP (individual placement and support)/vocational support
assessment
Date of conviction
Time to risk assessment completion Clinical, functional and recovery outcomes
Time to discharge from EIP HoNOS (Health of Nation Outcome Score)
Reason for discharge from EIP Change in employment/vocational status
Physical health Reduction in number of admissions, length of stays
General physical health information Reduction in ED attendance
Smoking status and intervention
Alcohol status and intervention
Weight assessment and management
Waist circumference
Fasting glucose
Lipid profile
Substance use assessment and management
Interventions
Offered cognitive–behaviour therapy
Offered family intervention
Offered employment support
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participant teams will be invited to participate in the
anonymised survey.
Recruitment of participants to focus groups
Patient, carer and staff focus groups will be conducted.
A purposive sample will be recruited of individuals who
meet the inclusion criteria. On the basis of previous
qualitative research involving individuals with schizo-
phrenia,25 it is expected that 15–20 individuals for each
set of stakeholders will need to be recruited for this
study to reach a point of data saturation (ie, no new
insights can be gained and information provided begins
to repeat itself). Focus groups will be composed of 6–8
individuals.26
Patients
Initial contact with potential participants will be made
by care coordinators or care professionals. Interested
individuals will then be contacted by the research team
via phone or in person. In other cases, interested indivi-
duals may contact the research team directly, through
self-referral via a study advertisement, by phone or in
person. Study advertisements will be posted in the par-
ticipant sites. After contact has been established, indivi-
duals will meet with the research team to discuss the
study and be provided with an informational sheet. If
the individual is interested in participating in the study,
informed consent will then be obtained. Individuals will
be given as much time as needed to determine whether
they would like to participate in the study.
Family/caregivers
Interested carers of people who are part of the pathway
will be contacted via care coordinators or they may
contact the research team directly, through self-referral
via a study advertisement, by phone or in person. Study
advertisements will be posted in the participant sites.
After contact has been established, individuals will meet
with the research team to discuss the study and be pro-
vided with an informational sheet. If the individual is
interested in participating in the study, informed
consent will then be obtained. Individuals will be given
as much time as needed to determine whether they
would like to participate in the study. Informed consent
will be obtained prior to the focus group taking place.
Clinicians
Interested individuals may contact the research team dir-
ectly, through self-referral via a study advertisement, by
phone or in person. Study advertisements will be posted
in the participant sites. After contact has been estab-
lished, individuals will meet with the research team to
discuss the study and be provided with an informational
sheet. If the individual is interested in participating in
the study, informed consent will then be obtained.
Focus group procedures
Participants will be invited to participate in a focus
group in a quiet room. A safe environment will be
chosen which is known to the individuals. Focus groups
will be led by staff trained in conducting qualitative
studies involving people with psychosis. Written
informed consent will be sought from participants.
Once consent has been received, the participants will
participate in a 1–2 hour (max) focus group. At the
beginning of the focus group, participants will be asked
to ﬁll out a demographic information sheet.
Participants may withdraw themselves from the focus
groups, if they so choose. If a participant chooses to
withdraw after a focus group starts, it will not be possible
to remove their data.
Analysis of data
The distribution of the quantitative variables will be
tested by Kolmogorov-Smirnov or Shapiro-Wilk tests, as
appropriate. If their distribution differs from the
Gaussian (normal) distribution, they will be presented
by median and IQR. Continuous variables (eg, the ques-
tionnaire scores at baseline) will be compared among
centres using t-tests while categorical variables (eg,
gender) will be compared using χ2 or Fisher’s test. End
of therapy scores on various outcome measures before
and after the intervention will be measured using paired
t-test. A process evaluation will be undertaken ‘to
explain discrepancies between expected and observed
outcomes, to understand how context inﬂuences out-
comes, and to provide insights to aid implementation’.27
Differences between the Intervention and Control
groups will be measured using a linear regression. The
statistical software package SPSS will be used for all eva-
luations as licenced to the Southern Health NHS
Foundation Trust.
Comparison between pre-intervention and post inter-
vention scores in satisfaction questionnaire will be made
by parametric and non-parametric tests. Where required
question analysis will be used to analyse data for emer-
ging themes.
Qualitative data analysis
Qualitative analysis will be used to explore focus group
discussions on the acceptability of the psychosis pathway
to patients, carers and staff as well as their range of
behaviours and perceptions, including barriers to its
implementation. Thematic content analysis will be used
to identify emerging themes from focus group and indi-
vidual interviews with staff, carers and patients. Data will
be audio-recorded and transcribed verbatim and emer-
gent themes generated. Data analysis will involve the
researchers immersing themselves in data by reading
and re-reading the interview transcripts to identify emer-
ging themes. Field notes will also be analysed for non-
verbal communication and behaviours and compared to
interview data. Each group will consist of six to eight par-
ticipants who will be approached by researchers,
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experienced in qualitative research. NViVO—a qualita-
tive data management software package—will be used to
store and code data. Content data will be recorded and
transferred for analysis using NVivo. Triangulation of
themes will be conducted to assess reliability and validity
of the analysis. Independent researchers will review a
selection of transcripts to check for accuracy in coding
of themes and reliability of interpretation. Verbatim
extracts will be included to support interpretation of
emergent themes.
Evaluation of direct costs
The evaluation of direct costs will be from a health
and social care and societal perspective. It will consist of
cost analysis for estimation of direct costs of care (eg,
average costs such as inpatient stay costs, crisis costs, ED
costs etc).
Data protection
The raw data (digital recordings, transcripts) will be
stored in encrypted form on a password-protected
network at the research department in Southern Health
NHS Foundation Trust. Consent documents, demo-
graphic forms, receipts for reimbursement of travel will
be stored in a locked ﬁling cabinet in the department.
Only research staff will have access to the above facilities.
Original consent forms from service users and staff
who wishes to take part in the interviews will be sent to
the research department in Southern Health NHS
Foundation Trust, and kept in the Study Master File.
Data will only be handled by senior trust staff who are
DBS checked and will comply with the Data protection
act and Information Governance policy of the trust. All
data will be completely anonymised for subsequent
graphical and statistical analyses.
STUDY SUPERVISION
Southern Health NHS Foundation Trust is the sponsor
for the study and, therefore, has overall responsibility for
the study along with the Chief Investigator (CI).
Following groups govern the conduct of this study:
▸ Psychosis pathway steering group: This group is
chaired by the ﬁrst author who is also CI of the study.
The membership includes key stakeholders, including
clinicians, managers, patient representative, commis-
sioners, Healthwatch representative, pathway facilita-
tor, a primary care representative and a representative
from the AHSN. Key strategies for successful imple-
mentation and monitoring are planned in this group.
▸ Data Monitoring and Ethics group: This group is
attended by the CI, pathway facilitator, a representa-
tive from AHSN, research department manager, statis-
tician and study manager. Data and ethics of the
study are discussed in this group.
▸ Study management group: This group is attended by
the study team, including CI, study manager, research
facilitators, pathway facilitator, representatives from
the participant sites, including principal investigators
and trial facilitators. The Study Management Group
oversees the day-to-day management of the study.
ETHICAL CONSIDERATIONS
The ethical issues in this study will be related to the
identiﬁcation and recruitment of patients, the proced-
ure for gaining fully informed consent and data protec-
tion arrangements. Written informed consent will be
obtained from every participant.
Ethics approval for this study was obtained from East
of Scotland Research Ethics Service (EoSRES) (REC Ref
no. LR/15/ES/0091).
Declaration of Helsinki
This study complies, and at all times will comply, with
The Declaration of Helsinki, as adopted at the 18th
World Medical Association (WMA) General Assembly,
Helsinki, Finland, 1964 and last amended at the 64th
WMA General Assembly, Fortaleza, Brazil, October 2013.
DISSEMINATION OF STUDY RESULTS
The results will be disseminated through publica-
tions, conference presentations, and reports to the
organisation.
Safety assessments
The development of the pathway ensured that it was tai-
lored to the needs of people with psychosis. As the inter-
vention is a service improvement, no adverse events are
anticipated as a direct result of implementation of the
pathway.
DISCUSSION
Evidenced-based integrated pathways have been used
successfully in stroke and cardiovascular illness. They
provide a standardised framework for good clinical prac-
tice, reduce variation in care and have improved out-
comes for patients through providing timely access and
intervention. Standardised pathways improve quality by
improving multidisciplinary communication with differ-
ent care agencies using care planning, and improve
patient satisfaction.22 While currently there are pathways
and guidance available for psychosis care in some coun-
tries such as UK,14 they do not provide prescriptive time-
frames to improve access to care and interventions. In
the UK, the access and waiting time standard28 has been
introduced to begin to address these issues and reduce
the DUP in ﬁrst episode psychosis. However, an
Integrated Care Pathway provides far more beneﬁts than
meeting a target in terms of providing personalised
good quality care.
Development of the pathway
The strength of the Integrated Care Pathway TRIumPH
is in its development through inspiring shared vision
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and purpose, patient empowerment through coproduc-
tion and codesign; intelligent use of information; inﬂu-
encing; and systems networking across interfaces
through stakeholder engagement, to incorporate diverse
views and impact on quality outcomes for patient care.
Codesigning services with clinicians and patients
together makes a difference to quality improvement, as
it draws from the expertise of patients, who are experts
by experience and professional leaders.29 The recent
Mental Health Taskforce report30 recommends that
Integrated Care Pathways are developed for mental
health conditions to reduce fragmented care and
improve outcomes.
Evaluation
There is a huge potential to improve quality and prod-
uctivity in mental health services.31 32 Across the world
initiatives have been taken in community services but
there are few evaluations of effectiveness or efﬁciency.33
There is also a need for standardisation and guidelines
on conducting such studies.
If the results of the study show that the pathway is feas-
ible, of beneﬁt to patients, carers and staff, the study
protocol will set a benchmark against which organisa-
tions can organise and audit their practice, which can
also be used to evaluate the effectiveness of service
changes. For practitioners, they will provide practical
guidance about what to do and when to do it, making
best use of their professional skills. The pathway can also
assist in establishing workforce and training need, such
as professional, therapy, vocational and support worker
time and training.
Limitations
Most organisations are currently struggling to balance
the quality versus ﬁnance agenda due to ongoing auster-
ity. Limited resources within services to deliver care
along the pathway may impact on results. These may
include inadequate numbers of clinicians in teams with
an understanding of the pathway and trained therapists
to deliver the interventions. Adaptation and adoption of
the pathway in other developed countries like the
United States and Canada may have challenges due to
system differences, hospital-based care and different
payment systems. Similarly, there maybe challenges in
developing countries where care is hospital-based and
attributions to illness and help-seeking pathways into
care are culturally inﬂuenced.
CONCLUSION
In conclusion, the TRIumPH study will provide evidence
for the feasibility, acceptability and impact of an
Integrated Care Pathway that has been developed
through intelligent use of information, coproduction
with patients, carers and clinicians and engagement with
wider stakeholders. If the pathway is successful, the
design of the intervention and study will allow a rapid
dissemination within the NHS.
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